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ABSTRACT
This paper reviews gas chromatography-mass spectrometry (GC-MS) methods for the analysis of amphetamines, ketamines,
opioids, cocaine, and other abused drugs in urine that were developed by authors in Taiwanese institutions, and published during the
2000 to early 2008 period. Information on sample preparation, derivatization, internal standard, GC column, detection mode, and
validation data for the reported methods are summarized in table format to facilitate readers’ reference and adaptation.
Key words: Review, GC-MS, amphetamines, ketamine, cocaine, opioids

INTRODUCTION
The identification and quantification of abused
substances and their metabolites in urine have been a
major task in the forensic drug testing industry. Ideally,
the adopted methodology should be robust and capable of generating analytical data of utmost accuracy.
Current practice requires the use of two assays based on
different analytical principles. First, immunoassays are
frequently used for urine screening in order to differentiate between negative and presumptively positive samples.
Positive results must be confirmed by a second independent method. Mass spectrometry, particularly in combination with chromatographic techniques, has become a
preferred tool in forensic science. Today, gas chromatography–mass spectrometry (GC-MS) is the most widely
used method for confirmation of positive tests (1-4), since
it provides high levels of specificity and sensitivity. The
mandatory Guideline for Abused Drug Urine Testing
in Taiwan is also based on the GC-MS as confirmation
method.
The GC-MS procedures were reviewed in many
studies. In 1992 Maurer (2) has discussed the systematic toxicological analysis of drugs and their metabolites by GC-MS. Goldberger and Cone (3) have reviewed
the confirmational tests for drugs in the workplace by
GC-MS. Kraemer and Maurer (4) have reviewed the
principal information on GC-MS procedures for the
* Author for correspondence. Tel: +886-3-3283201 ext. 2619;
Fax: +886-3-3311843; E-mail: meichich@gmail.com

determination of amphetamine, methamphetamine and
amphetamine derived designer drugs in 1998. Chen et
al.(5) have reviewed the determination of ketamine and its
metabolites in biological samples.
With the implementation of workplace urine drug
testing policy in Taiwan, researchers in various Taiwanese institutions have made substantial efforts to develop analytical methods suitable for this application. We
thought it would be informative to prepare a review
focusing on this narrowly defined scope — Papers
published by these Taiwanese authors during the 2000 to
early 2008 period. Information hereby provided would
complement earlier reviews(2-5) that were mainly based
on papers published by American and European authors.
Procedures are critically reviewed for the determination
of amphetamines, ketamine, opioids and other abused
drugs in human urine. Because of length limitation of the
report, a descriptive comparison of different analytical
procedures is not included. Likewise, animal studies are
not described since sufficient human studies are available
to adequately describe metabolism of the drugs in urine.
Basic information about the sample extraction
method, derivatization, internal standard, GC column,
detection mode and validation data of each procedure are
summarized in tables. The tables are organized based on
the drug class. The sample preparation is summarized in
the “Extraction method, derivatization agent” column.
The selection of the internal standard (I. S.) is given in the
“Internal standard” column. The principal information on
the GC column and on the detection mode is listed. Validation data like recovery (REC), linearity (LIN), limit of
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detection (LOD), and limit of quantification (LOQ) are
summarized in the “Validation data” column. The “Validation data” column indicates whether a paper deals with
a quantitative assay. Precision data was omitted since all
reviewed procedures were suitable for urine analysis.
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REC: 89-95%
LIN: 100-50000 ng/mL
LOD: 19-50 ng/mL
LOQ: 21-100 ng/mL
DB-5 100-280/10°C

isotope dilution MS, EI, SIM

REC: ?
LIN: 100-9600 ng/mL
LOD: ?
LOQ: ?
EI, Full scan, SIM

REC: ?
LIN: 50 - 20000 ng/mL
LOD: ?
LOQ: ?
EI, Full scan, SIM

AM-d8
MA-d8
AM
MA

SFE, TFAA

SPE, PFPA
MA-2H9
MA

HP-Ultra-1
100-300/20°C
LLE, TCAA, MSTFA, PFPA
MA-d5
MA-d8
MA-d9
MA

Detection mode
Column
Extraction method,
Derivatization agent
Internal
standard
Compound

Table 1. GC-MS procedures for the identification and quantification of amphetamines in human urine

Amphetamine (AM, R, S-1-phenyl-2-propanamine)
and methamphetamine (MA, R, S-N-methyl-1- phenyl2-propanamine) are powerful stimulants in the central
nervous system. These drugs are often abused and used
doping agents in sports (6). Stimulants in doping control
consists of a heterogeneous group of compounds,
the majority of which is structurally related to
amphetamine (6). There are many designer amphetamines,
such as 3,4-methylenedioxyamphetamine (MDA),
3,4-methylenedioxy methamphetamine (MDMA, Ecstasy), 3,4-methylenedioxyethylamphetamine (MDEA),
3,4-methylenedioxyphenyl-2-butamine
(MDB)
and
N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
(MBDB)(7). In addition, amphetamine and methamphetamine are the metabolic products of other drugs such as
amphetaminil, benzphetamine, clobenzorex, selegiline
(deprenyl), dimethylamphetamine, ethylamphetamine,
famprofazone, fencamine, fenethylline, fenproporex,
furfenorex, mefenorex, mesocarb, and prenylamine (8-10).
Most of the GC-MS procedures for the determination
of amphetamines in urine followed the same principles,
i.e. extraction, derivatization, separation, and detection
(Table 1). Extraction was performed using liquid-liquid
extraction (LLE) at an alkaline pH, at which the amphetamines are unionized(11-14) by solid-phase extraction
(SPE)(15-18). Note that the traditional LLE suffers from
lengthy and complicated operation procedure, excessive
use of harmful organic solvents, high background, and
low level of automation whereas conventional SPE may
suffer from cartridge clogging. A simultaneous supercritical fluid extraction (SFE) and chemical derivatization
(CD) procedure for the determination of amphetamines
in urine was described and evaluated by Wang et al.(19)
Because the trend towards automation and miniaturization has resulted in improved techniques of sample preparation, solid-phase microextraction (SPME) has been
increasingly popular. A one-step process (17) was adopted
to complete the absorption/derivatization process for the
analysis of amphetamines’ enantiomeric compositions by
adding the derivatizing reagent directly into the sample
matrix in a regular sample vial.
Derivatization of the amphetamines is necessary
to improve their GC properties to form more characteristic mass spectral fragment ions. Amphetamines
were derivatized prior to GC analysis by trifluoroacetic
anhydride (TFAA)(14,19,20), pentafluoropropionic anhydride (PFPA)(13,15,16), and acetic anhydride (AA)(18).
(S)-(−)-N-(trifluoroacetyl)-prolyl (l-TPC) was used to

Validation data

AMPHETAMINES

AM-d8
MA-d8

AM-d8
MA-d8
MDA-d5
MDMA-d5

AM-d8
MA-d8

AM-d8
MA-d8

AM-d8
MA-d8

MA-d8

AM
MA
MDA
MDMA
MDEA
and others

AM
MA

AM
MA
MDA
MDMA
MDEA

AM
MA
(Famprofazone)

PMMA
PMA
and others

Internal
standard

d-AM
l-AM
d-MA
l-MA

Compound

Table 1. Continued

HP-1 60-300/20°C

HP-5
90-240/15°C
to 300/10°C
Enantiomers:
150-250/20°C

LLE, TFAA, l-TPC

LLE, HFBA

CP-Wax capillary 52 CB
130-260/15°C

HP-5
60-250/25°C

HP-5
70-250/30°C

HP-5
60-250/25°C

Column

SPE, AA

LLE, PFPA

LLE, TFAA,

SPME, l-TPC

Extraction method,
Derivatization agent

EI, SIM

EI, SIM

Furan
C I-MS/MS, Full scan, SIM

EI, SIM

EI, Full scan, SIM

EI, Full scan, SIM

Detection mode

REC: ?
LIN: 100-2000 ng/mL
LOD: ?
LOQ: ?

REC: 85- 119%
LIN: 100-8000 ng/mL
LOD: 100 ng/mL
LOQ: 100 ng/mL

REC: 86 – 113%
LIN (ng/mL):
1-1000 (AM), 2-1000 (MA)
LOD (ng/mL):
1 (AM), 0.4 (MA), 0.5 (MDA), 0.5 (MDMA),
0.5 (MDEA)
LOQ (ng/mL):
2 (AM), 1 (MA), 1 (MDA), 1 (MDMA),
1 (MDEA)

REC: 75%
LIN: 50-1000 ng/mL
LOD: 40 ng/mL
LOQ: 50 ng/mL

REC: ?
LIN: 0-1000 ng/mL
LOD (ng/mL):
11 (AM), 19 (MA), 11(MDA), 12 (MDMA),
11 (MDEA)
LOQ (ng/mL):
20 (AM), 20 (MA), 25(MDA), 25(MDMA),
25 (MDEA)

REC: ?
LIN: 50 - 1000 ng/mL
LOD: 30 ng/mL
LOQ: 50 ng/mL

Validation data
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form diastereomers for chiral analysis (14,17). Different
chemical derivatization approaches were applied to meet
analytical needs. Further details on derivatization for the
analysis of drugs by GC-MS were discussed in the study
of Lin et al.(21) Commonly used derivatization reagents
for silylation, acylation, and alkylation were summarized
along with comments on practical considerations (21).
After derivatization, the analytes were separated on
capillary columns and detected in the single-ion monitoring (SIM) mode (13,14,19) or a combination of full scan and
SIM mode (11,12,15,17,18).
The selection of the is essential to ensure precision of the method. Stable isotopes are the most suitable
I.S., since they have the same analytical properties as
the corresponding analyte. Specifically, AM-d8, MA-d8,
MDA-d 5, and MDMA-d 5 were more favorable isotopes
(Table 1). Nevertheless, ion-pairs (analyte/I.-S.) contributed to the quality of quantitation results for the analysis
of methamphetamines (11,15). Methamphetamine 2H9 -analog was used as a sample to study the effect of molecular
abundance on the intensity ratio of an ion-pair that was
designated for the analyte and I.S.(15). Chang et al.(15)
claimed that the intensity ratio of an ion-pair selected to
designate the sample’s analyte-to-2H-I.S. concentration
ratio changes with the following operating parameters: (a)
constitution solvent volume; (b) injection volume, and (c)
column temperature program rate. Molecular abundance
(intensity) in ion source and different retention times
between analyte and its I.S. are the two main causes of
the interfering phenomenon. Lin et al.(11) suggested that
derivatization methods (trimethylsilyl-, trichloroacetyland pentafluoropropionyl-), internal standards (MA-d 5,
MA-d8, MA-d9), and ion-pairs all contribute to the quality of quantitation results for the analysis of methamphetamines. Furthermore, Chen et al.(22) developed an
approach to assess accuracy of the cross-contribution
data between the ions designating the analyte and the
deuterated I.S. They concluded that the normalized ion
intensity data can be reliably used for the calculation of
cross-contribution values, at least for the systems studied.
They further demonstrated that an ion-pair with about
5% (or higher) cross-contribution would result in a very
limited linear calibration range. Chiu et al.(16) also stated
that different retention times and intensities between
the methamphetamine and its isotopic 2H-analogs I.S.
seemed to have caused the observed interference in the
calibration curve.
Although methamphetamine is one of the two major
drugs of abuse in Taiwan(23), Lua et al.(24) showed a
high prevalence of ketamine (K) and MDMA detection
in urine samples from participants in a disco clubs in
Taiwan. Detailed analysis of the drugs of abuse profiles
in club urine samples and Detainee’s samples revealed
a very different pattern. K and MDMA positive rates
were extremely high in club urine samples. Therefore,
simultaneous detection and determination of AM, MA,
MDA, MDMA, MDEA, K, Norketamine (NK), and

dehydronorketamine (DHNK) in urine samples to monitor abuse of multiple drugs was reported(20). In this procedure, urine samples were extracted with organic solvent
and derivatized with TFAA, although only a few investigators have reported the derivatization of ketamines prior
to GC-MS analysis.
Famprofazone is one of the 14 amphetamine precursors and is a component of the multi-ingredient medication used for pain relief (Gewolen®)(25). Famprofazone is
included in the prohibited list of the World Anti-Doping
Agency(6). This drug has been demonstrated to metabolize to methamphetamine and amphetamine following administration and produce positives in urine drug
tests (26,27). A case report (14) showed that a urine specimen
collected during a national sport competition in Taiwan
tested positive for both methamphetamine and amphetamine. The athlete claimed that she had taken Gewolen®.
This study has demonstrated effectiveness of using
l-TPC as derivatization agent for separation of the d- and
l-enantiomers of amphetamine and methamphetamine.

KETAMINES
Ketamine is synthesized and marketed as an anesthetic drug for human and animal use (28,29). NK and
DHNK, the main metabolites of K (30), have been abused
and caused deaths(24,31). This abuse trend has created a
need for clinical laboratories to develop methods for the
analysis of K and its metabolites in biological matrices.
K and its major metabolite are usually determined with
GC-MS.
Sample preparation involves isolation, cleavage of
conjugates and/or derivatization of the K and its metabolites. Isolation was performed by LLE usually at an alkaline pH(12,32-35) or by SPE (36,37). Cleavage of conjugates
has been reported by Lin and Lua (32). In order to determine the presence of conjugated metabolites during K
metabolism, urine samples were hydrolyzed with concentrated hydrochloric acid, alkalinized and extracted with
organic solvent. Electron impact mode was employed to
determine K, NK, and DHNK. The acidic hydrolysis led
to a significant increase of K, NK, and DHNK concentration in many samples analyzed. The median concentration ratio of hydrolyzed to unhydrolyzed K, NK, and
DHNK was 1.15, 1.35, and 1.44, respectively.
While derivatization of the ketamine was
not necessary(32,33,36,37), several procedures with
derivatization(12,34,35) were used in this paper (Table 2).
As shown in the ‘‘Validation data’’ column in Table 2, all
procedures with or without derivatization led to similar
results.
Nevertheless, some authors stated that their analytical procedures have specific advantages. For example, an
analytical scheme using GC-isotope dilution mass spectrometry (IDMS) assisted by precedent LLE and chemical derivatization was described by Chou et al.(34) The

K-d4
NK-d4

K-d4
NK-d4

K-d4
NK-d4

K-d4
NK-d4

K-d4
NK-d4

K
NK

K
NK
DHNK

K
NK
DHNK
and others

K
NK
DHNK

Internal
standard

K
NK
DHNK

Compound
HP-5
110-180-270/5-45°C

HP-5
100-250/25°C (EI)
70-150-250/30-25°C (PCI)

HP-5
120-220-260/35-40°C

HP-5
70-250/30°C

HP-5
100-280/25°C

LLE, PFBC

LLE

LLE, TFAA

LLE, AA, TFAA, HFBA,
PFBC and other silylation
reagents

Column

LLE

Extraction method,
Derivatization agent

Table 2. GC-MS procedures for the identification and quantification of ketamines

EI, Full scan, SIM

EI, Full scan, SIM

EI, SIM

GC/isotope dilution MS,
EI, PCI, Full scan, SIM

EI, Full scan, SIM

Detection mode

REC: ?
LIN: ?
LOD (ng/mL):
AA- 5 (K), 3 (NK), 20 (DHNK)
TFAA- 5 (K), 3 (NK), 10 (DHNK)
HFBA: 10 (K), 3 (NK), 5 (DHNK)
PFBC: 5 (K), 3 (NK), 5 (DHNK)
LOQ (ng/mL):
AA- 5 (K), 5 (NK), 50 (DHNK)
TFAA- 5 (K), 5 (NK), 10 (DHNK)
HFBA: 10 (K), 5 (NK), 5 (DHNK)
PFBC: 5 (K), 5 (NK), 5 (DHNK)

REC: ?
LIN: 0-250 ng/mL
LOD (ng/mL):
2 (K), 1 (NK), 6 (DHNK)
LOQ (ng/mL):
20 (K), 20 (NK), 30 (DHNK)

REC: ?
LIN (ng/mL):
1-7000 (K), 5-4000 (NK), 20-5000 (DHNK)
LOD (ng/mL):
1 (K), 5 (NK), 20 (DHNK)
LOQ (ng/mL):
5 (K), 10 (NK), 40 (DHNK)

REC: 71-97.8 %
LIN: 100 - 5000 ng/mL
LOD (ng/mL):
EI- 10 (K), 5 (NK)
PCI- 75 (K), 50 (NK)
LOQ (ng/mL):
EI- 15 (K), 10 (NK)
PCI- 100 (K), 75 (NK)

REC: ?
LIN: 0-500 ng/mL
LOD (ng/mL):
1 (K), 5 (NK)
LOQ (ng/mL):
5 (K), 10 (NK)

Validation data
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34

32
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K-d4
NK-d4

K
NK
and others

SPE

SPE

Extraction method,
Derivatization agent

SPE,
MSTFA, BSTFA, BSA,
MBTFA, TFA, HFBA, PFPA,
AA

LLE,
1. methoxyamine and
hydroxylamine
2. TMS or propionyl group

MO-d 3, MO-d6,
CO-d3, CO-d6,
6-AMO-d3,
6-AMO-d6, and
others

MO
CO
6-AMO
and others

Extraction method,
Derivatization agent

MO-d3
CO-d3

Internal standard

HP-5
160-250/20°C

Rtx-5
100-250/20°C

Column

HP-5
130-170-200-250/10-5-10°C

MO
CO

Compound

Column
HP-5
130-170-200-280/10-5-40°C

Table 3. GC-MS procedures for the identification and quantification of opiods

K-d4
NK-d4

Internal
standard

K
NK
DHNK

Compound

Table 2. Continued

EI, Full scan, SIM

Isotope dilution
EI, PCI, NCI,
Full scan SIM

Detection mode

EI, Full scan, SIM

EI, Full scan, SIM

Detection mode

REC:
MO-propionyl-TMS (74.1%)
CO-TMS (86.5%)
6-AMO- propionyl (86.3%)

REC: 60.7 – 83.6% (MO)
65.2 – 90.2% (CO)
LIN: 50 - 1000 ng/mL
LOD (ng/mL):
EI- 1.1 (MO), 1.4 (CO)
PCI- 6.1 (MO), 1.3 (CO)
LOQ (ng/mL):
EI- 3.5 (MO), 4.7 (CO)
PCI- 14.2 (MO), 4.3 (CO)

Validation data

REC: 71.4 – 96.5% (K)
68.4 – 90.1% (NK)
LIN: 30 - 600 ng/mL
LOD (ng/mL):
15 (K), 5 (NK)
LOQ (ng/mL):
15 (K), 20 (NK)

REC: 53.4 – 77.9%
LIN: 30 - 1000 ng/mL
LOD (ng/mL):
10 (K), 10 (NK), 10 (DHNK)
LOQ (ng/mL):
15 (K), 10 (NK), 20 (DHNK)

Validation data

39

41

Ref
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LIN: ?
LOD and LOQ (ng/mL):
MO-propionyl-TMS: 30
MO-2 propionyl: 200
CO-TMS: 50
CO- propionyl: 100
6-AMO- propionyl: 30

REC: ?
LIN (ng/mL)::
0 – 500 (BUP), 0-1000 (NBUP)
LOD and LOQ (ng/mL):
Acetyl- 5 (BUP), 2.5-10 (NBUP)
TMS- 10 (BUP) , 5-50 (NBUP)
EI, Full scan, SIM
Toxi-Tubes A, LLE,
HP-5
MBTFA, BSTFA, AA, TFAA, 120-250-300/40-10°C
PFPA, HFBA, MSTFA with
1% TMCS (or BSTFA with
1% TMCS )
BUP-d4
NBUP-d3
BUP
NBUP

Compound

Table 3. Continued

Internal standard

Extraction method,
Derivatization agent

Column

Detection mode

Validation data

Ref

40
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simultaneous derivatization of the primary-amine NK
and secondary-amine K with pentafluorobenzoyl chloride
(PFBC) not only enhanced their instrumental responses
and mass-spectrum uniqueness, but also allowed more
appropriate and easier selection of qualifier and quantifier ions and hence achieved better identification and
quantitation. GC-IDMS operated in the PCI (positive
ion chemical ionization) mode could offer both qualitative and quantitative information complementary to those
given by the EI mode. Unfortunately, the authors did not
incorporate DHNK into the analyte list. Although Chou
et al.(34) utilized PFBC as the derivatization reagent
to develop the analytical procedure for K and NK, no
data was shown for other derivatization approaches. A
comparative study on the utilization of different derivatization groups for the analysis of K and NK was performed
by Wu et al.(35) Their results showed that the ion intensity
levels of K from various derivatization reagents were in
the following order: PFBC > TFAA > acetic anhydride
> BSTFA (N,O-bis (trimethylsilyl)trifluoroacetamide)
> MSTFA (N-methyl-bis(trifluoroacetamide)) > HFBA
(heptafluorobutyric anhydride) > MBTFA (N-methylbis(trifluoroacetamide)). The corresponding order for
NK and DHNK was PFBC > HFBA > TFAA > MBTFA >
BSTFA > MSTFA > acetic anhydride. Authors (35) claimed
that PFBC provided the best performance characteristics.
Lin and Lua (12) pointed out that an advantage of derivatization with that TFAA was that it did not produce a falsepositive result for MA under a simultaneous detection of
amphetamines, ketamines and a high concentration of
ephedrine or pseudoephedrine in urine sample.

OPIOIDS
Both codeine and heroin are metabolized to
morphine by the hepatic enzymes(38). Codeine is biotransformed via O-demethylation to morphine under
the catalysis of cytochrome P450 enzyme. Nevertheless,
heroin is first deacetylated to 6-acetylmorphine via blood
esterase and later hydrolyzed to morphine in the liver.
Buprenorphine is a semi-synthetic organic compound
with a chemical structure similar to morphine. Currently,
this drug is prescribed as an alternative to methadone for
the treatment of heroin addiction. Its main metabolite is
desalky-BUP or norbuprenorphine (NBUP).
Sample preparation was performed by LLE (39) or
Toxi-Tube A(40) or SPE (41). Since 6-acetylmorphine was
an important metabolite, the analytical protocol did not
include a hydrolysis step (41). The study data showed the
concentrations of these drugs/metabolites in their free
forms. Wang et al.(41) presented a more detailed comparison accompanied by GC-IDMS methodology on the CDs
of MO and CO, with twelve CD agents. Efficiency of the
CD, analyte-IS ion cross-contribution, shelf-life of the
derivative, and experimental conditions of the CD were
also evaluated in this study. The results demonstrated

240

46
REC: ?
LIN: 80-200 ng/mL
LOD: 2.5 ng/mL
LOQ: 5.0 ng/mL
EI, SIM
LLE, MSTFA
7-amino-FM 2-d7
7-amino-FM2

HP-5
150-300/20°C

44
REC: 72.4-82.1%
LIN: 125 - 1500 ng/mL
LOD: 62.5 ng/mL,
LOQ: 125 ng/mL,
EI, SIM
SPE, BSTFA-TMCS
Dextromethorphan
Pentazocine

DB-5
150-280/20°C

43
REC: 2 3.7% (LLE), 60.7% (SPE)
LIN: 500 - 10000 ng/mL
LOD: 300 ng/mL (LLE) 100 ng/mL (SPE)
LOQ: 500 ng/mL (LLE) 200 ng/mL (SPE)
HP-5
60-100-250/15-25°C
GHB-d6
GHB

SPE, LLE,
BSTFA

EI, Full scan, SIM

42
HP-Ultra-1, Parameters
were adapted in the literature
for various CD products.
Cocaine-d3
Benzolecgonine-d3
Benzolecgonine-d8
Cocaine
Benzolecgonine
and others

LLE,
TFAA, PFPA, HFBA, MSTFA
with 1% TMCS, MTBSTFA
with 1% t-BDMCS, and others

EI, Full scan, SIM

REC: ?
LIN: ?
LOD:,?
LOQ: ?

Validation data
Detection mode
Column
Extraction method,
Derivatization agent
Internal standard

Relatively limited papers concerning applications of
GC-MS to cocaine (42), gamma-hydroxybutyrate (GHB)
(43)
, pentazocine (44) and 7-aminoflunitrazepam (7-aminoFM 2)(45,46) were available to date.
Chemical derivative products of the analyte and
the selected I.S. must generate ions able to indicate
the analyte and the I.S. These ions should not have
significant cross-contribution, such as I.S. contribution to the intensities of the ions designated for the
analyte and vice versa (47-50). However, researches have
been demonstrated analyte-I.S. ion cross-contribution
for amphetamines (11,15), ketamines (35), opioids(39,41),
buprenorphine (40) and barbitals (51,52). In addition, Wang
et al.(42) further evaluated the isotopically labeled internal standards and derivatization methods for quantitative determination of cocaine and related compounds, i.e.
norcocaine, benzoylecgonine, cocaethylene, ecgonine,
ecgonine methyl ester, anhydroe cgonine methyl ester.
The isotopically labeled analogs of the analytes were
used as internal standards (Table 4). In addition to the
systematic presentation of full scan spectra, the cross-

Compound

OTHER ABUSED SUBSTANCES

Table 4. GC-MS procedures for the identification and quantification of cocaine, gamma-hydroxybutyrate, pentazocine, and 7-aminoflunitrazepam

that SPE and BSA (N,O-bis(trimethylsilyl)acetamide)-CD
followed by GC-IDMS was a sound analytical scheme for
the conclusive determination of MO and CO in urine (41).
However, 6-acetylmorphine was not included. The validation data for the MO-BSA and CO-BSA are presented
in Table 3.
An ethoxyimino/propionyl/TMS (trimethylsilyl) threestep derivatization approach was developed for the simultaneous analysis of 8 opioids: morphine, codeine, 6-acetylmorphine, hydromorphone, oxymorphone, hydrocodone,
oxycodone, and noroxycodone(39). Distinct derivatization
products, with good chromatographic and mass spectrometric characteristics, were generated for all analytes. Chen et
al.(39) indicated that application of methoxyimino/propionyl/TMS groups, in the order listed, facilitated the simultaneous analysis of these 8 opiates in urine samples and led to
satisfactory LOD, LOQ and linearity (Table 3).
Various chemical derivatization approaches adapted
for the analysis of buprenorphine and its major metabolite (norbuprenorphine) were conducted by Wu et al.(40)
These approaches included alkylation, acylation, and
silylation resulting in the formation of methyl, acetyl,
trifluoroacetyl, pentafluoropropionyl, heptafluorobutyryl,
and trimethylsilyl derivatives. The criteria included reaction yields and ionization efficiency of the derivatization
products, chromatographic characteristics, cross-contributions to the intensities of ions designating the analytes,
and the internal standards. Among all acetyl- and TMSderivatization approaches studied, derivatization by
acetyl anhydride resulted in the best performance characteristics. Unfortunately, the authors published no recovery data.
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contribution data of these ion pairs were evaluated using
data collected under the SIM mode. The data exhibited
similar cross-contribution characteristics in each alkyl,
acetyl or TMS series. The cross-contribution data derived
from the use of I.S. labeled with more deuterium atoms
were generally more favorable.
A paper was published on the determination of GHB
with simultaneous extraction and BSTFA-CD followed
by GC-EIMS SIM(43). GHB as its BSTFA derivative was
recovered from urine in 23.7% through the LLE-CD
procedure, in contrast to 60.7% via the SPE-CD counterpart. The validation data are shown in Table 4. SPE
protocol provided lower LOD and LOQ than did the LLE
protocol. However, in acidic media, an average of 23.8%
of γ-butyrolactone (GBL) was hydrolyzed into GHB,
whereas 11.8% of GHB was converted to GBL.
Collaborative study was carried out on the determination of pentazocine in urine by GC-MS(44). This
method used SPE and BSTFA with 1% TMCS derivatization, followed by GC-MS analysis using dextromethorphan as the internal standard (Table 4). The analytical
protocol was further applied to an inter-laboratory study.
Nine drug-abuse urine testing laboratories in Taiwan
participated in the collaborative study. All of the testing
laboratories passed their own quality control and were
accredited by the National Bureau of Controlled Drugs
(NBCD), Department of Health, Executive Yuan, Taiwan,
R.O.C. Individual analysts in each laboratory were given
flexibility while following the established criteria. Specifically, minimum performance criteria with system suitability test had to be met, but analysts were encouraged
to use their routine analytical system (e.g., instrument,
injector and column) and to use individual judgment in
adjusting the operating conditions. Moreover, a GC-MS
method for the analysis of 7-amino-FM 2 in urine (45) was
subjected to an inter-laboratory collaborative study(46).
LLE and MSTFA derivatization were performed and
7-amino-FM 2- d7 was used as the internal standard (Table
4). Authors concluded that the methods (44-46) showed
acceptable repeatability and reproducibility.

CONCLUSIONS AND PERSPECTIVES
Most publications on abused drug analysis with
GC-MS published in the last decade by Taiwanese
researchers emphasized investigating and improving the
extraction and derivatization methods, internal standards
and ion-pairs. These factors all contribute to the quality
of quantitation results. Most of the procedures are suitable for routine clinical and forensic purposes.
In Taiwan, there are two legal precursor drugs,
famprofazone and seligiline, which are metabolized by
the body to AM and MA. Famprofazone is an antipyretic and analgesic multi-ingredient medication containing famprofazone, acetaminophen (paracetamol),
propyphenazone and caffeine. Two legally and locally

manufactured brand name medicines (Gewolen® tablet
and Paisao® capsule) containing famprofazone are found
on the Department of Health website in Taiwan(53). From
a forensic standpoint, it is important that the precursor drugs are controlled and dispensed by prescription.
Unfortunately, famprofazone can be purchased in many
drug stores without prescription. Thus, famprofazone
users may lack a valid medical prescription to help the
interpretation and usage. Neugebauer et al.(54) reported
that urine from a famprofazone user contained 2831 ng/
mL of MA and 567 ng/mL of AM. Results also showed
that the l-enantiomer of MA exceeded that of the d-form.
As a consequence of the discussion on false positive MA
results, NBCD instructed its certified drug-abuse urine
testing laboratories that at least 100 ng/mL of AM must
be present in urines which are positive for MA＞500 ng/
mL. Note that misinterpretation of positive immunoassay
and even GC-MS results is possible because the parent
compound is not detectable for as long as the two metabolites AM and MA. Since the AM and MA metabolized
from famprofazone contain both the d- and l-enantiomers,
detection of the parent drug and its metabolites, together
with the concentrations and enantiomeric composition of
AM and MA, is highly valuable for the determination of
the involvement of this drug.
Another precursor drug, seligiline, is a prescription
agent used for the treatment of Parkinson disease and
depression. It produces l-amphetamine and l-methamphetamine metabolites, which give a positive result on
immunoaassays (55). Unfortunately, routine GC-MS also
does not distinguish between the 2 isomers and requires
chiral chromatography to differentiate between the dand l- forms(9).
To date only a few papers were published by
Taiwanese researchers on the determination of AMand MA-generating precursors, their metabolites and
enantiomers. Excretory studies (especially in the later
phase of excretion) should be performed to prove whether
enantiomeric profiles for AM and/or MA metabolically
formed from precursor drugs will allow the differentiation in relation to the abuse of illicit AM and/or MA.
The ring-methoxylated phenethylamine derivatived paramethoxyamphetamine (PMA) and paramethoxymethamphetamine (PMMA) are structurally related to the MDMA, MDA and MDEA compounds. These
drugs exhibit all hallucinogenic properties(56). Following the 8 recent PMM A fatalities reported by Lin et al.
in Taiwan, biological fluid specimens including heart
blood, gastric, bile, and urine were tested. Other drugs,
such as MDA, MDMA, K, NK, hydroxymidazolam, MA,
and pentobarbital, were also found in these cases (56).
However, PMMA were not detectable in routine analytical procedures in many laboratories. Thus, rarely occurring designer drugs such as PMA or PMMA could not be
discovered by routine analytical methods.
Stimulants and narcotic analgesics have been
subjects of doping control analysis since the International
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Olympic Committee’s drug testing program in 1967. At
that time, gas-liquid chromatography and thin-layer chromatography were performed for the doping controls.
Subsequently, more comprehensive screening and also
specific confirmation procedures based on GC-MS
were established and are still employed in sports drug
testing(57-61). The method of choice for screening procedures covered more than 200 target analytes plus new
and unknown derivatives or designer drugs. This should
be taken into account when amending the lists of banned
substances. It is important for our researchers to continue
developing analytical techniques for new, undetectable
and identifiable substances.

LIST OF ABBREVIATIONS

MDB

3,4-methylenedioxyphenyl-2-butamine

MDEA

3,4-methylenedioxyethylamphetamine

MDMA

3,4-methylenedioxymethamphetamine

MO

Morphine

MSTFA

N -methyltrimethylsilyltrifluoroacetamide

MTBSTFA

N-methyl-N-(t-butyldimethylsilyl)trifluoroacetamide

NBCD

National Bureau of Controlled Drugs

NBUP

Norbuprenorphine

NK

Norketamine

PCI

Positive ion chemical ionization

PFBC

Pentafluorobenzoyl chloride

PFPA

Pentafluoropropionyl anhydride

AA

Acetyl anhydride

PMA

Paramethoxyamphetamine

AM

Amphetamine

PMMA

Paramethoxymethamphetamine

AMO

6-Acetylmorphine

REC

Recovery

t-BDMCS

t-butyldimethylchlorosilane

SFE

Supercritical fluid extraction

BSA

N,O-bis(trimethylsilyl)acetamide

SIM

Single-ion monitoring

BSTFA

N,O-bis(trimethylsilyl)trifluoroacetamide

SPE

Solid-phase extraction

BUP

Buprenorphine

SPME

Solid-phase microextraction

CO

Codeine

TCAA

Trichloroacetic anhydride

CD

Chemical derivatization

TFAA

Trifluoroacetic anhydride

DHNK

Dehydronorketamine

TMS

Trimethylsilyl

EI

Election impact ionization

TMCS

Trimethylchlorosilane

GBL

Gamma-butyrolacton

TPC

(S)-(−)-N-(trifluoroacetyl)-prolyl chloride

GC

Gas chromatography

GC-MS

Gas chromatography-mass spectrometry

GHB

Gamma-hydroxybutyrate

HFBA

Heptafluorobutyric anhydride

IDMS

Isotope dilution mass spectrometry

I.S.

Internal standard

K

Ketamine

LIN

Linearity

LLE

Liquid-liquid extraction

LOD

Limit of detection

LOQ

Limit of quantification

MA

Methamphetamine

MBDB

N-methyl-1-(3,4-methylenedioxyphenyl)-2butanamine

MBTFA

N-methyl-bis(trifluoroacetamide)

MDA

3,4-methylenedioxyamphetamine
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